Unnamed: 0,title,date,stock,sentiment
1197510.0,Supernus Pharma Files For Non-Timely 10Q,2020-05-12 14:17:00-04:00,SUPN,positive
1197511.0,Supernus To Purchase CNS Portfolio From US WorldMeds For $300M In Upfront Cash Payment Plus Cash Milestone Payments Up To $230M,2020-04-28 17:00:00-04:00,SUPN,neutral
1197512.0,Supernus and Navitor Announce Development and Option Agreement for Orally Active mTORC1 Activator NV-5138; Navitor To Receive $25M Upfront Payment and Potential $410M-$475M In Milestones,2020-04-21 16:21:00-04:00,SUPN,positive
1197513.0,"Stifel Maintains Hold on Supernus Pharmaceuticals, Lowers Price Target to $24",2020-04-16 11:04:00-04:00,SUPN,negative
1197514.0,Supernus Announces Phase III P302 Trial Of SPN-810 For Treatment Of IA In ADHD Patients 6 To 11 Years Old Did Not Meet Primary Endpoint,2020-02-25 16:44:00-05:00,SUPN,neutral
1197515.0,"Supernus Sees FY20 Operating Earnings $70M-$100M, Net Product Sales $360M-$390M",2020-02-25 16:41:00-05:00,SUPN,neutral
1197516.0,Supernus Pharma Shares To Resume Trade At 4:45 p.m. EST,2019-12-09 16:23:00-05:00,SUPN,positive
1197517.0,UPDATE: Results Showed Median Percent Reduction of 58.6% In The Average Weekly Frequency Of Impulsive Aggression,2019-12-09 16:22:00-05:00,SUPN,negative
1197518.0,Supernus Pharmaceuticals Provides Results From Its Phase 3 Study Of SPN-9810 For The Treatment Of Impulsive Aggression In ADHD Patients,2019-12-09 16:21:00-05:00,SUPN,negative
1197519.0,Supernus Pharma Offers Update On Results From Phase 3 Study Of SPN-810 For Treatment Of Impulsive Aggression In ADHD Patients: Baseline Was Not Statistically Significant Vs. Placebo,2019-12-09 16:17:00-05:00,SUPN,negative
1197520.0,Supernus Pharma Shares Halted News Pending,2019-12-09 16:10:00-05:00,SUPN,positive
1197521.0,Supernus Pharma Reports Submission Of New Drug Application for SPN-812 For Treatment Of ADHD,2019-11-11 16:16:00-05:00,SUPN,neutral
1197522.0,"Stifel Nicolaus Downgrades Supernus Pharmaceuticals to Hold, Lowers Price Target to $23",2019-11-07 06:49:00-05:00,SUPN,negative
1197523.0,Jefferies Downgrades Supernus Pharmaceuticals to Hold,2019-11-06 06:35:00-05:00,SUPN,neutral
1197524.0,"Supernus Pharma Shares Resume Trade, Down 24.5%",2019-11-05 17:25:00-05:00,SUPN,positive
1197525.0,Supernus Pharma Shares To Resume Trade At 5:25 p.m. EST,2019-11-05 17:02:00-05:00,SUPN,positive
1197526.0,"Supernus Pharmaceuticals Q3 EPS $0.54 Misses $0.6 Estimate, Sales $102.14M Miss $109.54M Estimate",2019-11-05 17:02:00-05:00,SUPN,negative
1197527.0,Supernus Pharma Reports Phase 3 P301 Trial Of SPN-810 For Treatment Of IA In ADHD Patients 6-11 Did Not Meet Primary Endpoint,2019-11-05 17:02:00-05:00,SUPN,neutral
1197528.0,Supernus Shares Halted News Pending,2019-11-05 16:40:00-05:00,SUPN,positive
1197529.0,Supernus Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 sales results. The company also cut FY19 net product sales guidance.,2019-08-06 17:51:00-04:00,SUPN,negative
1197530.0,Supernus Pharmaceuticals Cuts FY19 Net Product Sales Guidance From $435M-$455M To $400M To $410M,2019-08-06 17:47:00-04:00,SUPN,negative
1197531.0,"Supernus Pharmaceuticals Q2 EPS $0.61 Beats $0.57 Estimate, Sales $104.695M Miss $108.67M Estimate",2019-08-06 17:45:00-04:00,SUPN,negative
1197532.0,'Goldman Sachs is sounding the alarm to clients that technology stocks are overvalued' -Earlier CNBC Article,2019-06-17 10:10:00-04:00,SUPN,negative
1197533.0,"Supernus Pharmaceuticals Q1 EPS $0.34 Misses $0.47 Estimate, Sales $85.474M Miss $103.87M Estimate",2019-05-07 17:58:00-04:00,SUPN,negative
1197534.0,Supernus Announces P304 Phase III Data Confirming 'Positive' Results From Previous Three Phase III Studies On SPN-812 In ADHD; Reached Statistical Significance Compared To Placebo In Primary Endpoint,2019-03-28 08:06:00-04:00,SUPN,positive
1197535.0,"Supernus Pharmaceuticals Q4 EPS $0.48 Beats $0.27 Estimate, Sales $115.934M Beat $105.4M Estimate",2019-02-26 17:59:00-05:00,SUPN,neutral
1197536.0,"Supernus Shares Resume Trade, Not Yet Seeing Updated Last Price",2018-12-20 07:47:00-05:00,SUPN,positive
1197537.0,Supernus Reports Phase III Study For SPN-812 In Adolescents With ADHD Met Primary Endpoint,2018-12-20 07:19:00-05:00,SUPN,neutral
1197538.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018",2018-12-19 12:43:00-05:00,SUPN,negative
1197539.0,Supernus Pharma Reports FDA Approved Of sNDA To Expand Oxtellar XR Label To Include Monotherapy,2018-12-14 16:02:00-05:00,SUPN,positive
1197540.0,"Supernus Pharma Shares Resume Trade, Down 10%",2018-12-06 09:00:00-05:00,SUPN,positive
1197541.0,Supernus Pharma Shares To Resume Trade At 9 a.m. EST,2018-12-06 08:38:00-05:00,SUPN,positive
1197542.0,"Supernus Reports Results From 2 Phase III Studies For SPN-812 In Children With ADHD: P301, P303 Met Primary Endpoint",2018-12-06 07:02:00-05:00,SUPN,neutral
1197543.0,Supernus Shares Halted News Pending,2018-12-06 06:59:00-05:00,SUPN,positive
1197544.0,"B. Riley FBR Maintains Buy on Supernus Pharmaceuticals, Lowers Price Target to $65",2018-11-12 12:55:00-05:00,SUPN,negative
1197545.0,"upernus Pharmaceuticals, Inc. Sees Narrows FY18 Sales Guidance Fro m$385M-$400M To $388M-$395M vs $398.7M Est.",2018-11-06 17:30:00-05:00,SUPN,neutral
1197546.0,"Supernus Pharmaceuticals, Inc. Q3 EPS $0.52 Beats $0.39 Estimate, Sales $102.996M Beat $101.84M Estimate",2018-11-06 17:29:00-05:00,SUPN,neutral
1197547.0,"Mizuho On Supernus Pharma: Buy Stock Into ADHD Data Catalyst; Reiterates Buy, $61 Price Target",2018-10-29 07:16:00-04:00,SUPN,neutral
1197548.0,"Mizuho Initiates Coverage On Supernus Pharmaceuticals with Buy Rating, Announces $61 Price Target",2018-09-18 06:15:00-04:00,SUPN,neutral
1197549.0,Supernus Raises FY18 Research & Development Expenses Guidance From $80M To $95M,2018-09-13 16:19:00-04:00,SUPN,neutral
1197550.0,Supernus Raises Narrows FY18 Net Product Sales Guidance From $375M-$400M To $385M-$400M vs $401.54M Est.,2018-09-13 16:18:00-04:00,SUPN,neutral
1197551.0,"Supernus To Acquire Biscayne Neurotherapeutics ; Transaction Provides Upfront Payment Of $15M, Additional Payments Include $73M Contingent On Development Milestones And $95M Contingent On Sales Milestones",2018-09-13 16:16:00-04:00,SUPN,neutral
1197552.0,Supernus Reports Winning Of Appeal Related To Oxtellar XR Against TWi,2018-09-06 15:35:00-04:00,SUPN,positive
1197553.0,"Supernus Pharma 8-K Shows Enrollment In Phase 3 Studies For SPN-812 Ahead Of Schedule, Complete In P301, P302, P303 Studies, Data Expected In Q4'18",2018-09-04 17:19:00-04:00,SUPN,neutral
1197554.0,"Supernus Pharma Narrows FY18 Guidance: Net Product Sales From $375M-$400M To $385M-$400M vs $403.9M Estimate, Raises Operating Earnings From $125M-$135M To $130M-$140M",2018-08-07 16:43:00-04:00,SUPN,neutral
1197555.0,"Supernus Pharmaceuticals Q2 EPS $0.57 Beats $0.43 Estimate, Sales $99.5M Miss $99.86M Estimate",2018-08-07 16:23:00-04:00,SUPN,negative
1197556.0,Supernus Pharmaceuticals Sees FY2018 Sales $375.0M-400.0M vs $398.50M Est,2018-05-08 16:56:00-04:00,SUPN,neutral
1197557.0,"Supernus Pharmaceuticals Q1 EPS $0.49 Beats $0.33 Estimate, Sales $90.429M Beat $85.29M Estimate",2018-05-08 16:55:00-04:00,SUPN,neutral
1197558.0,"Supernus Reports Q4 EPS $0.26 vs $0.27 Est., Sales $88.44M vs $87.28M Est.",2018-02-27 17:09:00-05:00,SUPN,neutral
1197559.0,"Supernus Pharma Shares Now Up 3% For Session, Over $39 Level; BZ NOTE: Name Has Not Previously Been Mentioned By The Rumor Mill",2018-02-08 12:16:00-05:00,SUPN,positive
1197560.0,Supernus Shares Up Almost $1 Over Last Few Mins. As Traders Circulating Chatter Co. Received Takeover Bid,2018-02-08 12:15:00-05:00,SUPN,positive
1197561.0,"Berenberg Initiates Coverage On Supernus Pharmaceuticals with Buy Rating, Announces $66.00 Price Target",2018-02-01 08:10:00-05:00,SUPN,neutral
1197562.0,"Several Biotechs Higher Tuesday Amid Jefferies Mention Of Price Increases In Effect; Insys +13.21%, Synergy Pharmaceuticals +6.72%, Allergan +3.22%, Horizon Pharma +0.99%, Supernus Pharma +0.25%, Teva Pharma +0.53%; Collegium An Outlier, Down 0.64%",2018-01-02 12:26:00-05:00,SUPN,neutral
1197563.0,Janney Capital Upgrades Supernus Pharmaceuticals to Buy,2017-12-04 07:36:00-05:00,SUPN,neutral
1197564.0,Stifel Nicolaus Upgrades Supernus Pharmaceuticals to Buy,2017-11-08 07:26:00-05:00,SUPN,neutral
1197565.0,"Suntrust Out Defending Supernus, Says They Would Take Advantage Of Weakness As Potential In Trokendi XR With 40 New Sales Reps Added",2017-11-07 11:58:00-05:00,SUPN,negative
1197566.0,"Supernus Shares Down 13.5% Tues. Morning Despite Q3 Earnings Beat, Raised Guidance Mon. Afternoon; Cantor Analyst Said Stock's 'weak recent performance may be attributable to confusion regarding interim look at SPN-810 pivotal program and discontinuation'",2017-11-07 10:38:00-05:00,SUPN,negative
1197567.0,Supernus Pharmaceuticals FY17 Sales Outlook Raised From $280M-$290M to $290M-$295M vs $295.89M Est.,2017-11-06 17:01:00-05:00,SUPN,neutral
1197568.0,"Supernus Pharmaceuticals Reports Q3 EPS $0.29 vs $0.27 Est., Sales $80.398M vs $77.6M Est.",2017-11-06 17:00:00-05:00,SUPN,neutral
1197569.0,"FBR Capital Initiates Coverage On Supernus Pharmaceuticals with Buy Rating, Announces $53.00 Price Target",2017-10-19 08:25:00-04:00,SUPN,neutral
1197570.0,Stifel Nicolaus Downgrades Supernus Pharmaceuticals to Hold,2017-09-19 07:12:00-04:00,SUPN,neutral
1197571.0,"Supernus Pharmaceuticals Shares Resume Trading, Down 4.13%",2017-09-18 16:31:00-04:00,SUPN,positive
1197572.0,Supernus Pharma Shares To Resume Trade At 4:30 p.m. EDT,2017-09-18 16:19:00-04:00,SUPN,positive
1197573.0,"Supernus Announces Interim Results From Phase III Trial Of SPN-810, Will Eliminate 18mg Dosing Arm, Will Randomize Patients To Increase Probability Of Reaching Statistically Significant Outcome",2017-09-18 16:05:00-04:00,SUPN,positive
1197574.0,"Supernus Pharmaceuticals Shares Halted, News Pending",2017-09-18 16:03:00-04:00,SUPN,positive
1197575.0,Supernus Announces US District Court Ruled TWi Pharma Infringed On Its Patent,2017-08-15 17:01:00-04:00,SUPN,neutral
1197576.0,"Supernus Pharma Reports Q2 EPS $0.32 vs $0.24 Est., Sales $75.829M vs $67.8M Est.",2017-08-02 17:09:00-04:00,SUPN,neutral
1197577.0,PiperJaffray Downgrades Supernus Pharmaceuticals to Neutral,2017-07-17 06:09:00-04:00,SUPN,neutral
1197578.0,"Janney Capital Initiates Coverage On Supernus Pharmaceuticals with Neutral Rating, Announces $47.00 Price Target",2017-07-14 06:37:00-04:00,SUPN,neutral
1197579.0,Supernus Pharma Reports Partner Shire Received FDA Approval For Mydayis For ADHD,2017-06-21 12:38:00-04:00,SUPN,positive
1197580.0,"PiperJaffray Upgrades Supernus Pharmaceuticals to Overweight, Raises Price Target to $44.00",2017-06-01 06:03:00-04:00,SUPN,negative
1197581.0,Supernus Sees FY17 Sales $265-$275M vs $275M Est.,2017-05-09 16:25:00-04:00,SUPN,neutral
1197582.0,"Supernus Reports Q1 EPS $0.19 vs $0.23 Est., Sales $56.4M vs $59.3M Est.",2017-05-09 16:24:00-04:00,SUPN,neutral
1197583.0,Supernus Reports Settlement with Actavis on Trokendi XR Patent Litigation,2017-03-07 13:07:00-05:00,SUPN,negative
1197584.0,"Supernus Announces Settlement With Zydus On Patent Litigation, Agrees To Permit Zydus To Sell Generic Version Of Trokendi on Jan. 1, 2023 Or Earlier Under Certain Circumstances",2017-03-06 17:31:00-05:00,SUPN,positive
1197585.0,Supernus Reports Issuance of Eighth U.S. Patent Protecting Trokendi XR,2017-02-08 07:06:00-05:00,SUPN,neutral
1197586.0,"Supernus Reports  Issuance of Seventh U.S. Patent Protecting Trokendi XR, Provides Protection Until 2027",2017-01-30 07:06:00-05:00,SUPN,neutral
1197587.0,"Supernus Files Form 10-Q for Third Quarter 2016, Is Now Current with All Financial Filings",2017-01-23 11:14:00-05:00,SUPN,neutral
1197588.0,"Cantor Fitzgerald Initiates Coverage On Supernus Pharmaceuticals at Overweight, Announces $32.00 Target",2016-12-16 09:04:00-05:00,SUPN,negative
1197589.0,Supernus Reports Winning of Appeal Case on Oxtellar XR,2016-12-12 16:30:00-05:00,SUPN,positive
1197590.0,Northland Securities Downgrades Supernus Pharmaceuticals to Market Perform,2016-07-18 09:33:00-04:00,SUPN,positive
1197591.0,Piper Jaffray Downgrades Supernus Pharmaceuticals to Neutral,2016-07-18 06:18:00-04:00,SUPN,neutral
1197592.0,"Jefferies Upgrades Supernus Pharmaceuticals to Buy, Maintains $18.00 PT",2016-02-08 06:21:00-05:00,SUPN,neutral
1197593.0,"Jefferies Upgrades Supernus Pharmaceuticals to Buy, Maintains $18.00 PT",2016-02-08 06:14:00-05:00,SUPN,neutral
1197594.0,"Northland Securities Initiates Coverage on Supernus Pharmaceuticals at Outperform, Announces $26.00 PT",2015-10-28 09:39:00-04:00,SUPN,positive
1197595.0,Supernus Announces FDA Acceptance of sNDA to Add Migraine to Trokendi XR Label,2015-10-22 18:39:00-04:00,SUPN,positive
1197596.0,"Jefferies Upgrades Supernus Pharmaceuticals to Buy, Raises PT to $18.00",2015-06-18 06:23:00-04:00,SUPN,neutral
1197597.0,SunTrust Robinson Humphrey Initiates Coverage on Supernus Pharmaceuticals at Buy,2015-06-12 06:52:00-04:00,SUPN,neutral
1197598.0,"SUpernus Pharmaceuticals, Inc. Reports Q3 EPS of $0.39 vs $0.36 Est; Revenue of $52.50M vs $43.08M Est",2014-11-11 16:30:00-05:00,SUPN,neutral
1197599.0,Supernus Announces Fourth US Patent Protecting Oxtellar XR,2014-09-04 07:35:00-04:00,SUPN,neutral
1197600.0,"Supernus Pharmaceuticals, Inc. Sees FY2014 Sales $105.0M vs $80.10M Est",2014-08-11 17:07:00-04:00,SUPN,neutral
1197601.0,"SUpernus Pharmaceuticals, Inc. Reports Q2 EPS of $0.08 vs $(0.16) Est; Revenue of $27.60M vs $19.85M Est",2014-08-11 17:06:00-04:00,SUPN,neutral
1197602.0,"SUpernus Pharmaceuticals, Inc. Reports Q1 EPS of $(0.38) vs $(0.41) Est; Revenue of $9.08M vs $9.94M Est",2014-05-12 17:38:00-04:00,SUPN,neutral
1197603.0,"Jefferies Initiates Coverage on Supernus Pharmaceuticals, Inc. at Hold, Announces $9.00 PT",2014-04-21 16:42:00-04:00,SUPN,neutral
1197604.0,"Stifel Nicolaus Maintains Buy on Supernus Pharmaceuticals, Inc., Raises PT to $14.00",2014-03-14 06:45:00-04:00,SUPN,neutral
1197605.0,"SUpernus Pharmaceuticals, Inc. Reports Q4 EPS of $(0.65) Which May Not Compare $(0.55) Est; Revenue of $10.30M Which May Not Compare $7.78M Est",2014-03-12 16:31:00-04:00,SUPN,neutral
1197606.0,"SUpernus Pharmaceuticals, Inc. Reports Q3 EPS of $(0.78) vs $(0.67) Est; Revenue of $1.26M vs $2.54M Est",2013-11-12 16:01:00-05:00,SUPN,neutral
1197607.0,"SUpernus Pharmaceuticals, Inc. Reports Q2 EPS of $(0.89) vs $(0.65) Est",2013-08-13 16:20:00-04:00,SUPN,neutral
1197608.0,"Piper Jaffray Maintains Overweight on Supernus Pharmaceuticals, Inc., Lowers PT to $13.00",2013-05-14 10:10:00-04:00,SUPN,negative
1197609.0,"SUpernus Pharmaceuticals, Inc. Reports Q1 EPS of $(0.60) vs $(0.71) Est",2013-05-13 16:01:00-04:00,SUPN,neutral
1197610.0,"Piper Jaffray Maintains Overweight on Supernus Pharmaceuticals, Inc., Lowers PT to $14.00",2013-03-15 07:38:00-04:00,SUPN,negative
1197611.0,"SUpernus Pharmaceuticals, Inc. Reports Q4 EPS of $(0.51) vs $(0.71) Est; Revenue of $109.0K vs $60.0K Est",2013-03-14 16:42:00-04:00,SUPN,neutral
1197612.0,"Jefferies Initiates Coverage on Supernus Pharmaceuticals, Inc. at Buy, Announces $13.00 PT",2013-03-05 06:16:00-05:00,SUPN,neutral
1197613.0,"From Earlier: Lazard Capital Markets Initiates Coverage on Supernus Pharmaceuticals, Inc. at Buy, Announces $6.00 PT",2012-12-05 11:16:00-05:00,SUPN,neutral
1197614.0,"Citigroup Initiates Coverage Supernus Pharmaceuticals at Neutral , Announces PT of $14.00",2012-11-27 10:25:00-05:00,SUPN,neutral
1197615.0,Supernus Pharmaceuticals Reports Positive Phase IIb Results on SPN-810 for Treatment of Impulsive Aggression in ADHD Patients,2012-11-20 21:43:00-05:00,SUPN,positive
1197616.0,Supernus Awarded Patents Covering Trokendi XR,2012-11-05 07:26:00-05:00,SUPN,positive
1197617.0,"Piper Jaffray Maintains Supernus Pharmaceuticals at Overweight, Raises PT from $12 to $15",2012-08-13 07:45:00-04:00,SUPN,negative
1197618.0,"Citigroup Initiates Coverage On Supernus Pharmaceuticals at Neutral, Announces PT of $6",2012-06-29 14:32:00-04:00,SUPN,neutral
